drugset / Trial / NCT04076540
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers
Phase 1
Completed
48 enrolled
AstraZeneca
Eolas Therapeutics INC. · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase I, first-in-human (FIH), single-center, randomized, double-blind, placebo controlled, single ascending dose, sequential group study in healthy vasectomized male and female subjects of non-childbearing potential, aged 18 to 65 years.
Timeline
- Start
- 2019-10-03
- Primary completion
- 2022-01-02
- Completion
- 2022-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD4041 | Unknown | — | Oral |
Indications
No indication recorded.